Skip to content
Biodatica
Start free

Bayer

Multiple Locations, Bavaria

OncologyPhase IIListed · BAYRY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

2w agoTrial registeredJul 1, 2026Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jul 21, 2016

    Prostatic Neoplasms, Castration-Resistant · COMPLETED · sponsor: Bayer · Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

    ClinicalTrials.gov · NCT02803437 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jun 27, 2014

    Thyroid Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bayer · Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

    ClinicalTrials.gov · NCT02185560 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Aug 2, 2008

    Hypertension, Pulmonary · COMPLETED · sponsor: Bayer · Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

    ClinicalTrials.gov · NCT00694850 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources